Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol’s Sprycel To Launch “Within Days”

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA grants dasatinib accelerated approval for all phases of chronic myeloid leukemia in patients resistant to or intolerant of Novartis’ Gleevec.

You may also be interested in...



Bristol Counters Tasigna Approval With “Improved” Sprycel Labeling In CML

Chronic-phase CML patients are recommended to take dasatinib 100 mg once daily, a dose associated with the same efficacy and less fluid retention than twice daily 70 mg dosing.

Bristol Counters Tasigna Approval With “Improved” Sprycel Labeling In CML

Chronic-phase CML patients are recommended to take dasatinib 100 mg once daily, a dose associated with the same efficacy and less fluid retention than twice daily 70 mg dosing.

Bristol To Overcome Sprycel Uptake “Resistance” By Encouraging Faster Switching

Bristol-Myers Squibb reports modest sales of $25 million for Sprycel during the oncologic’s first six months on the market.

Related Content

Topics

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel